RESEARCH ARTICLE

Seroprevalence of Antibodies against *Plasmodium falciparum* Sporozoite Antigens as Predictive Disease Transmission Markers in an Area of Ghana with Seasonal Malaria Transmission

Kwadwo A. Kusi1*, Samuel Bosomprah2, Eric Kyei-Baafour1, Emmanuel K. Dickson1, Bernard Tornyigah1, Evelina Angov3, Sheetij Dutta3, Daniel Dodoo1, Martha Sedegah4, Kwadwo A. Koram5

1 Department of Immunology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Legon, Accra, Ghana, 2 Department of Biostatistics, School of Public Health, College of Health Sciences, University of Ghana, Legon, Accra, Ghana, 3 Malaria Vaccine Branch, Walter Reed Army Institute of Research, Silver Spring, MD, United States of America, 4 Malaria Department, Naval Medical Research Center, Silver Spring, MD, United States of America, 5 Department of Epidemiology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Legon, Accra, Ghana

*akusi@noguchi.ug.edu.gh

Abstract

Introduction

As an increasing number of malaria-endemic countries approach the disease elimination phase, sustenance of control efforts and effective monitoring are necessary to ensure success. Mathematical models that estimate anti-parasite antibody seroconversion rates are gaining relevance as more sensitive transmission intensity estimation tools. Models however estimate yearly seroconversion and seroreversion rates and usually predict long term changes in transmission, occurring years before the time of sampling. Another challenge is the identification of appropriate antigen targets since specific antibody levels must directly reflect changes in transmission patterns. We therefore investigated the potential of antibodies to sporozoite and blood stage antigens for detecting short term differences in malaria transmission in two communities in Northern Ghana with marked, seasonal transmission.

Methods

Cross-sectional surveys were conducted during the rainy and dry seasons in two communities, one in close proximity to an irrigation dam and the other at least 20 Km away from the dam. Antibodies against the sporozoite-specific antigens circumsporozoite protein (CSP) and Cell traversal for ookinetes and sporozoites (CelTOS) and the classical blood stage antigen apical membrane antigen 1 (AMA1) were measured by indirect ELISA. Antibody levels and seroprevalence were compared between surveys and between study communities.
Antibody seroprevalence data were fitted to a modified reversible catalytic model to estimate the seroconversion and seroreversion rates.

Results
Changes in sporozoite-specific antibody levels and seroprevalence directly reflected differences in parasite prevalence between the rainy and dry seasons and hence the extent of malaria transmission. Seroconversion rate estimates from modelled seroprevalence data did not however support the above observation.

Conclusions
The data confirms the potential utility of sporozoite-specific antigens as useful markers for monitoring short term/seasonal changes in malaria transmission. It may however be essential to update models to allow for assessment of seasonal changes in malaria transmission, which usually occur within four to six months.

Introduction
Monitoring of malaria transmission has become very crucial as a number of endemic countries continue to make tangible gains in disease control. According to the WHO, an increasing number of these countries are approaching the disease elimination phase [1]. Current standard tools for monitoring malaria transmission are largely insensitive and laborious to undertake in areas with low transmission and this presents a unique challenge to control and elimination programmes since a lapse in monitoring can easily result in a resurgence of malaria. The development of more sensitive monitoring tools will therefore be an essential component of control strategies.

*Plasmodium falciparum* infection elicits antibody responses to multiple stages of the parasite and the presence of these antibodies in the blood of persons with current and previous infections can be used as a marker of parasite exposure. Antibodies to parasite antigens such as apical membrane antigen 1 (AMA1), the 19 kDa fragment of merozoite surface protein 1 (MSP1₁₉) and merozoite surface protein 2 (MSP2) have all been used as biomarkers of malaria transmission in various endemic settings [2–4]. In areas of stable medium to high transmission, estimates of anti-AMA1, anti-MSP1₁₉ and anti-MSP2 antibody seroconversion rates from modeled cross-sectional data correlate well with standard entomological inoculation rate (EIR) estimates [2,3]. A recent sero-epidemiological study that utilized two longitudinal cohorts, the first with a one year follow up and the second with four years of follow up, identified three parasite antigens that could predict an individual’s exposure to parasites within 30, 90 or 365 days [5]. In addition, this study also identified six other parasite antigens, including CSP and MSP2, which effectively predicted the incidence of malaria in the preceding year [5]. These sero-epidemiological approaches to transmission estimation have an advantage over parasite prevalence estimation approaches since antibody decay is slower than parasite clearance rates. A downside to sero-epidemiological transmission estimation is however the persistence of antibodies long after transmission has ceased [6–8].

The sporozoite stages of *P. falciparum* are exposed to the immune system for a relatively short time after an infectious bite, compared to the asexual blood stage infection which can persist for much longer times, especially in asymptotically infected individuals. Sporozoite-
specific antibody levels have been shown, at least in an experimental human challenge study with sporozoite immunization, to increase with each immunization/challenge and declined in the absence of parasite exposure between immunization and challenge [9]. The levels of antibodies against sporozoite stage antigens are therefore expected to be relatively higher in individuals with frequent or recent exposure to infectious bites and lower in those with no recent exposure. We have previously shown in an area of very low malaria transmission that antibodies to two such sporozoite antigens, circumsporozoite protein (CSP) and cell traversal for ookinetes and sporozoites (CeTOS), indeed had relatively higher decay rates compared to the classical blood stage antigen AMA1 [10]. Reversible catalytic models based on seroprevalence of antibodies to CSP further predicted a 13-fold decrease in seroconversion rate and hence malaria transmission, an event which occurred approximately four years prior to the time of sampling in this area [10]. The association between anti-CSP antibodies and malaria transmission intensity as estimated by such modeled cross-sectional data are consistent with similar estimates based on longitudinal data [11–14].

It is however unclear how antibody seroconversion estimation models, which estimate yearly seroconversion rates based on cross-sectional antibody seroprevalence data, will be able to effectively predict short term changes in transmission that are observed within four to six months in areas of seasonal malaria transmission [15,16].

In the current study, we sought to evaluate a disease transmission intensity estimation model based on anti-sporozoite antibody seroprevalence for predicting short term changes in malaria transmission intensity in two communities in the Bongo District of the Upper East region of Ghana where malaria transmission is highly seasonal. Both communities have had a high penetration of malaria intervention tools such as insecticide-treated mosquito nets and intermittent treatment of malaria in pregnancy, either through programmes of the national health system or through studies that have been undertaken in the district for over two decades [17–19]. One of the study communities, Gowrie/Vea, is in close proximity to the Vea irrigation dam while Soe, the other study community, is at least 20 Kms away from the Vea dam. We therefore also sought to assess whether the large water body in one of the communities will result in differences in the intensity of malaria transmission between the two communities, and whether anti-sporozoite antibody seroprevalence and seroconversion rate estimates will be able to identify these differences. Estimates of seroconversion and seroreversion rates from the reversible catalytic model are based on a set of assumptions, one of which is that all individuals in a community, irrespective of age and frequency of exposure to infectious bites, serorevert to being specific antibody-negative at the same rate [20]. In the current study, the superinfection model [21], which is a modification of the reversible catalytic model and accounts for the effect of repeated infections on the decay rate of antigen-specific antibodies, was used to assess any changes in transmission intensity in the two study communities (Gowrie/Vea and Soe). The ultimate aim of the study was therefore to determine whether sero-epidemiological models based on seroprevalence of antibodies against sporozoite antigens could assess short term differences in transmission between the two seasons with different disease transmission dynamics.

Methods

Ethics statement

Ethical and scientific approvals for the study were granted by the Institutional Review Boards (IRB) and the Scientific and Technical Committees (STC) of both the Noguchi Memorial Institute for Medical Research (NMIMR, Study number 108/11-12) and the Navrongo Health Research Centre (NHRC, study number NHRCIRB142). Both NMIMR (FWAA00001824) and
NHRC (FWA00000250) hold a United States Government Federal Wide Assurance from the Office for Human Research Protections. Study participants or their parents/legal guardians gave written informed consent before enrollment into the study.

Study sites and sample collection

The study was conducted as part of an on-going immunological study in the Gowrie/Vea and Soe communities in the Bongo district of the Upper East region of Ghana (Fig 1). The Bongo district, like a few other districts in the region, has been mapped by the demographic surveillance system of the Navrongo Health Research Centre and the database is regularly updated. The study areas have marked seasonal malaria transmission that overlaps with rainfall and vector distribution patterns. The peak rainfall season has traditionally been from May to November, followed by a period of very dry conditions from December to April the following year. Malaria transmission in the two study communities is therefore high from June through November and comparatively lower between January and April.

Fig 1. Map of the study area showing the dam and non-dam study communities. Credit: Mr. Richard Adade, GIS & Remote Sensing Unit, Department of Fisheries and Aquatic Sciences, Center for Coastal Management, University of Cape Coast, Cape Coast, Ghana.

doi:10.1371/journal.pone.0167175.g001
The Gowrie/Vea community has a large water body, the Vea irrigation dam, for agricultural purposes while the Soe community is about 20 km away from the Vea dam. The proximity of the water body to one of the two study communities is expected to result in differences in transmission of a mosquito-borne disease such as malaria. A questionnaire-based study that assessed the impact of the Vea dam on the health of individuals in communities surrounding the dam reported participant-perceived increases in the prevalence of a number of water-associated diseases such as malaria and schistosomiasis [22]. Aside the presence of the dam, the two study communities are largely rural with similar ecology and most inhabitants are subsistence farmers.

Individuals living in the two selected communities were recruited for the study. A cross-sectional community-based survey was conducted close to the end of the rainy season in November/December 2012 and a second similar survey was conducted at the end of the dry season in April 2013 in both study communities. Study participants were screened for sexual and asexual stage parasitaemia by light microscopic examination of thick blood smears at each cross-sectional time point. Venous blood (2 to 3 ml) was drawn from participants to prepare plasma samples for serology and these were stored at -20°C until use. Basic clinical and demographic data of participants were also captured by questionnaire to aid data analysis and interpretation. Samples from 609 participants between one and thirty years were analyzed in this study.

**Antigens and ELISA**

Antigens used in this study were all from the 3D7 clone of *P. falciparum* and were expressed and purified under GMP conditions. The near full-length CSP protein containing 19 of the 38 NANP repeats was expressed in an *Escherichia coli* system [23]. The CelTOS protein is comprised of 174 amino acids including an N-terminal six-histidine tag within a 16-amino acid linker [24]. The AMA1 protein is comprised of amino acids 83 to 531 of the AMA1 ectodomain and was also expressed in *E. coli* [25,26].

Plasma levels of antibodies to the three parasite antigens were determined by a previously described indirect ELISA protocol [10]. Briefly, antigen-coated and blocked 96-well ELISA plates (Maxisorp, NUNC, Denmark) were incubated with 100 μl/well of duplicate test plasma samples diluted 1:1,000 in 1% non-fat milk in PBS. A pool of semi-immune sera was used as a standard calibrator (diluted 50 times for CSP, CelTOS and 5,000 times for AMA1 antigen plates) and titrated on each plate as an internal control. Plasma samples were incubated for two hours at room temperature and the plates subsequently developed with goat anti-human IgG conjugated to horseradish peroxidase (Invitrogen, CA, USA) followed by the substrate TMB (KEM-EN-TEC, Taastrup, Denmark). The colour reaction was stopped by the addition of 50 μl/well of 0.2 M H₂SO₄ and optical densities (ODs) were subsequently read at 450 nm using a 96-well ELISA plate reader (BioTek, VT, USA). In between all incubation steps, plates were washed five times with PBS, pH 7.4, 0.05% Tween 20 using an automated plate washer.

**Statistical and data analysis**

For each measured antibody, OD data were normalized against the internal assay control. A mixture model was then fitted to the normalized and log₁₀-transformed OD data from both communities over the two seasons to define a common cut-off value above which samples from both study communities were deemed antibody-positive as previously described [27]. Briefly, the distribution of log₁₀-transformed OD values was fitted as the sum of two Gaussian distributions using maximum likelihood methods; one of the two distributions represents the seronegative population and the other represents the seropositive population. For each antigen, the mean log₁₀-OD of the Gaussian corresponding to the seronegative population plus
log₁₀-three standard deviations was calculated, back-transformed and used as the cut-off for seropositivity. Seroprevalence was calculated as the proportion of samples with OD above this cut-off.

For each survey, the mean annual seroconversion rate (λ), which represents exposure to malaria over time and is analogous to the force of infection, and the mean annual seroreversion rate (ρ), the rate at which seropositive individuals revert back to seronegativity, were estimated using the superinfection model as described by Bosompra et al. [21]. This model which is a modification of the reversible catalytic model, accounts for the fact that antibody responses can be boosted in individuals who are already seropositive. The mean annual λ and ρ were fitted using maximum likelihood methods that assume a binomial error distribution. Seroprevalence curves were plotted using observed seropositivity data and the median age of ten age groups, each of which is a decile of the observed data. The fitted values and 95% confidence limits were also plotted and the resulting λ is presented for each survey time point. Evidence for temporal changes in λ was explored by fitting models in which λ is allowed to change at a single time-point. Akaike’s information criterion (AIC) was used to assess the significance of the change in λ against models with no change. Unlike the likelihood test, the AIC penalizes for the loss in degree of freedom. The model with the smallest AIC was considered to fit the data better. Profile likelihood plots were used to determine the most likely time that a change in λ, and hence transmission intensity, occurred.

For comparison of antibody levels between communities and sampling time points, OD data was converted into titres in arbitrary units (AU) using the 4-parameter logistic curve fitting program known as ADAMSEL (version b038, Ed Remarque, The Netherlands) and based on the positive plasma pool used as calibrator on each plate. Differences in antigen-specific antibody levels were assessed by comparing antibody levels (AU) in an age stratified manner (1–5 years, 6–15 years and 16–30 years). For each antigen, the Mann-Whitney U test was used to compare antibody levels between the two transmission seasons and between communities. The two-sample test for equality of proportions, with continuity correction, was used to compare proportions of parasite-positive individuals either between the two communities or between the two survey time points.

Analysis of data and graphics were performed using Stata (Statacorp, TX, USA) and R (version 3.2.2, R development Core Team). Differences were considered statistically significant when p values were less than 0.05.

Results

Study participant distribution and parasite prevalence

Plasma samples from a total of 609 study participants between one and thirty years were analyzed in this study. Of this number, 300 participants were from the rainy season survey (134 from Gowrie/Vea, the dam site, 166 from Soe, the non-dam site) and 309 from the dry season survey (147 from the dam site, 162 from the non-dam site). Study participants were categorized into three age groups, namely 1–5 years, 6–15 years and 16–30 years, and the proportions of individuals who had parasites, determined by light microscopy, were compared between the rainy and dry season for each age group. In the Gowrie/Vea community (dam site), parasite prevalence was significantly higher during the rainy season in the 1–5 year old (rainy season = 42%, dry season = 15.9%, p < 0.0001, two-sample test for equality of proportions) and 16–30 year old (rainy season = 34.3%, dry season = 2.2%, p < 0.0001) groups; there was no difference in parasite prevalence between the two seasons in the 6–15 year old group (rainy season = 30.6%, dry season = 31, p = 1). In the Soe community (non-dam site) however, parasite prevalence, in all three age groups, was at least two times higher in the rainy season compared
to that of the dry season (Table 1). Proportions of parasite-positive individuals were however not significantly different between the two communities for all age groups per season (\(p > 0.05\) in all cases), except for the higher proportion of parasite-positive 6–15 year old individuals in Soe (48.1%) compared to the proportion within the same age group in Gowrie/Vea (30.6%, \(p = 0.017\)). Further to this, for slide-positive individuals, there were no significant differences in median parasite density either between study communities or survey time points for any of the age groups (\(p > 0.05\) in all cases).

### Antigen-specific antibody levels and seroprevalence amongst study participants

Levels of antibodies, expressed as the titre in arbitrary units, were also compared between the two survey time points in an age-stratified manner. Median anti-CSP antibody titres in the rainy season were about seven to 17-fold higher compared to corresponding titres in the dry season for all age groups in the two communities (\(p < 0.0001\) in all cases, Table 2). Anti-CeTOS antibody titres were also about two to five-fold higher during the rainy season for all age groups in the two communities (\(p < 0.0001\) in all cases). Anti-AMA1 antibody titres were only significantly higher in the rainy season for the 1–5 year old group in Gowrie/Vea (the dam site, \(p = 0.039\)). Thus generally, antibody levels against the sporozoite-specific antigens (CSP and CeTOS) were higher during the rainy season compared to their levels in the dry season (Table 2).

Comparison of antibody titres between the two communities showed that the median titre of anti-CSP antibodies in the younger age group (1–5 years) were statistically significantly higher in Gowrie/Vea (Dam site) compared to the median titre in the same age group from Soe (Non-dam site) (\(p = 0.024\). Mann-Whitney U test, Table 2); the median antibody titre in the other age groups (6–15 years, 16–30 years) as well as median titres against the two other antigens (AMA1 and CeTOS) were however not different between the two communities.

For each antigen-specific antibody, the log_{10}-transformed OD data was fitted to a mixture model in order to define antigen-specific seropositive and seronegative populations (Fig 2). Anti-CSP antibody seroprevalence in both communities was significantly higher during the rainy season (Gowrie/Vea seroprevalence = 87.1%, 95%CI = 80.2–91.9%; Soe seroprevalence = 81.9%, 95%CI = 75.3–87.1%) compared to that of the dry season (Gowrie/Vea seroprevalence = 54.4%, 95%CI = 46.3–62.4; Soe seroprevalence = 49.1%, 95%CI = 41.4–56.8%). Seroprevalence of anti-CeTOS antibodies in both communities were also higher in the rainy season (Gowrie/Vea seroprevalence = 23.5%, 95%CI = 17.0–31.5; Soe seroprevalence = 28.3%, 95%CI = 21.9–35.7) compared to the dry season (Gowrie/Vea seroprevalence = 5.4%, 95%CI = 2.7–10.6%; Soe seroprevalence = 6.2%, 95%CI = 3.4–11.2, Table 3). Seroprevalence of

### Table 1. Comparison of parasite prevalence between surveys.

| Community          | Age group | % Parasite prevalence (n) | P value |
|--------------------|-----------|---------------------------|---------|
|                    | Rainy season | Dry season |         |
| Gowrie/Vea (Dam site) | 1–5 years | 42 (50) | 15.9 (44) | < 0.0001 |
|                    | 6–15 years | 30.6 (49) | 31 (58) | 1 |
|                    | 16–30 years | 34.3 (35) | 2.2 (45) | < 0.0001 |
| Soe (Non-dam site) | 1–5 years | 38 (58) | 17.5 (57) | 0.002 |
|                    | 6–15 years | 48.1 (54) | 22 (59) | 0.0002 |
|                    | 16–30 years | 30 (54) | 4.3 (46) | < 0.0001 |

Sample size (n) for each age category is indicated in brackets.

doi:10.1371/journal.pone.0167175.t001
anti-AMA1 antibodies were however not different between the two survey time points for any of the two communities (Table 3). Thus seroprevalence of antibodies against the two sporozoite-specific antigens were always higher in the rainy season while seroprevalence of antibodies to the classical blood stage antigen AMA1 did not differ between the rainy and dry seasons. For all three antigens, there were no differences in antibody seroprevalence between the two study communities at any of the two survey time points.

Table 2. Comparison of antigen-specific antibody levels between survey periods.

| Community          | Antigen | Age group (years) | Antibody levels (Arbitrary units) | P value |
|--------------------|---------|-------------------|-----------------------------------|---------|
|                    |         |                   | Rainy season                      | Dry season |       |
| Gowrie/Vea (Dam site) | AMA1    | 1–5               | 5312.8 (54.9–27712.8)             | 1569.9 (20.0–34877.9) | 0.039 |
|                    |         | 6–15              | 10179.1 (255.6–28046.0)           | 9136.1 (145.7–49456.8) | 0.93  |
|                    |         | 16–30             | 7157.0 (703.4–30361.1)            | 11899.0 (724.4–44888.4) | 0.33  |
|                    | CelTOS  | 1–5               | 346.0 (70.0–1203.1)               | 99.9 (19.7–864.6)      | < 0.0001 |
|                    |         | 6–15              | 596.4 (66.9–4631.5)               | 191.2 (35.9–6237.7)    | < 0.0001 |
|                    |         | 16–30             | 707.4 (151.2–3445.1)              | 178.8 (15.8–2469.7)    | < 0.0001 |
|                    | CSP     | 1–5               | 698.2 (120.4–9809.1)              | 41.4 (2.1–688.7)       | < 0.0001 |
|                    |         | 6–15              | 1672.0 (161.8–17534.6)            | 164.3 (14.9–1044.8)    | < 0.0001 |
|                    |         | 16–30             | 2476.6 (210.7–36554.9)            | 236.3 (44.9–2272.6)    | < 0.0001 |
| Soe (Non-dam site) | AMA1    | 1–5               | 3391.7 (73.1–26082.1)             | 722.9 (17.9–32022.0)   | 0.51  |
|                    |         | 6–15              | 12979.0 (142.2–27353.0)           | 9831.8 (80.8–43404.4)  | 0.85  |
|                    |         | 16–30             | 9056.7 (107.2–29156.7)            | 11469.0 (100.0–42390.1) | 0.54  |
|                    | CelTOS  | 1–5               | 222.8 (8.0–2830.8)                | 108.6 (10.9–492.1)     | < 0.0001 |
|                    |         | 6–15              | 648.7 (20.0–3100.0)               | 130.0 (20.5–1205.1)    | < 0.0001 |
|                    |         | 16–30             | 577.3 (7.0–13688.2)               | 186.0 (9.1–2483.1)     | < 0.0001 |
|                    | CSP     | 1–5               | 503.1 (55.0–10424.1)              | 56.4 (2.1–444.6)       | < 0.0001 |
|                    |         | 6–15              | 1271.6 (245.5–9336.1)             | 151.7 (10.7–1479.1)    | < 0.0001 |
|                    |         | 16–30             | 2070.7 (155.5–13874.5)            | 300.0 (35.8–1827.6)    | < 0.0001 |

Antibody levels expressed in arbitrary units and presented as median levels (min.–max.). P values obtained after Mann-Whitney test.

doi:10.1371/journal.pone.0167175.t002

Fig 2. Distribution of seronegative and seropositive populations per antigen. For each antigen, the log_{10}-transformed OD data from the two communities over the two seasons were combined and fitted to a mixture model. The mean log_{10}-OD of the Gaussian corresponding to the seronegative population plus log_{10}-three standard deviations was calculated, back-transformed and used as the cut-off for antigen-specific antibody seropositivity based on the distribution. Blue vertical lines in each case represent the estimated positivity cut-off values.

doi:10.1371/journal.pone.0167175.g002
Antigen-specific seroconversion and seroreversion rates

Antigen-specific seroprevalence curves for the rainy and dry seasons are presented in Figs 3 and 4 respectively, and seroconversion and seroreversion rate estimates are provided in Table 3. All seroprevalence curves were monophasic, suggesting that no changes in \( \lambda \) were observed within the two communities based on antibody seroprevalence data collected either during the rainy or dry season. A comparison of \( \lambda \) between survey time points however showed a statistically significant difference in \( \lambda \) between the rainy and dry season estimates for anti-CSP antibodies in both study communities and for anti-CelTOS antibodies in the non-Dam community (Soe) alone (Figs 3 and 4, Table 3). Anti-AMA1 antibody \( \lambda \) was not different between survey time points in both communities. For all antigen-specific antibodies, there were no significant differences in \( \lambda \) between the two study communities at any of the two survey time points (Table 3).

A comparison of antigen-specific \( \lambda \)s based on the combined data showed that rainy season anti-AMA1 \( \lambda \) (0.360, 95%CI 0.236–0.550) was statistically similar to that of anti-CSP \( \lambda \) (0.414, 95%CI 0.300–0.571), and both were significantly higher than that of anti-CelTOS antibodies \( \lambda = 0.055, 95\%CI 0.032–0.092 \). During the dry season, anti-AMA1 antibody \( \lambda \) for the combined data (0.208, 95%CI 0.135–0.321) was significantly higher than anti-CSP \( \lambda \) (0.078, 95%CI 0.053–0.110) and anti-CelTOS \( \lambda \) (0.007, 95%CI 0.002–0.022). Anti-CSP \( \lambda \) was also significantly higher than anti-CelTOS \( \lambda \) during both the rainy and dry seasons (Table 3). These collectively suggest that antibodies against AMA1 and CSP form at a significantly faster rate than those

---

**Table 3. Annual seroconversion and seroreversion rate estimates by the superinfection model based on antigen-specific antibodies.**

| Antigen | Survey | Site | Number of subjects (N = 609) | % seropositive (95%CI)* | Seroconversion rate (95%CI) | Reversion rate (95%CI) |
|---------|--------|------|-----------------------------|-------------------------|-----------------------------|-----------------------|
| AMA1    | Rainy season | Dam | 134 | 61.4 (52.7, 69.3) | 0.354 (0.180, 0.696) | 0.299 (0.128, 0.698) |
|         |        | No Dam | 166 | 64.5 (56.8, 71.4) | 0.369 (0.213, 0.639) | 0.273 (0.137, 0.541) |
|         | Both | 300 | 63.1 (57.4, 68.4) | 0.360 (0.236, 0.550) | 0.282 (0.165, 0.480) |
|         | Dry season | Dam | 147 | 53.1 (44.9, 61.0) | 0.189 (0.098, 0.365) | 0.179 (0.071, 0.451) |
|         | No Dam | 162 | 56.5 (48.7, 64.0) | 0.224 (0.127, 0.396) | 0.194 (0.088, 0.427) |
|         | Both | 309 | 54.9 (49.3, 60.4) | 0.208 (0.135, 0.321) | 0.189 (0.104, 0.344) |
| CelTOS  | Rainy season | Dam | 134 | 23.5 (17.0, 31.5) | 0.040 (0.019, 0.086) | 0.064 (0.011, 0.374) |
|         | No Dam | 166 | 28.3 (21.9, 35.7) | 0.071 (0.035, 0.144) | 0.135 (0.047, 0.393) |
|         | Both | 300 | 26.2 (21.5, 31.5) | 0.055 (0.032, 0.092) | 0.099 (0.040, 0.248) |
|         | Dry season | Dam | 147 | 5.4 (2.7, 10.6) | 0.008 (0.001, 0.042) | 0.064 (0.001, 0.281) |
|         | No Dam | 162 | 6.2 (3.4, 11.2) | 0.007 (0.002, 0.031) | 0.033 (0.000, 0.755) |
|         | Both | 309 | 5.8 (3.7, 9.1) | 0.007 (0.002, 0.022) | 0.045 (0.002, 1.217) |
| CSP     | Rainy season | Dam | 134 | 87.1 (80.2, 91.9) | 0.500 (0.292, 0.857) | 0.121 (0.036, 0.410) |
|         | No Dam | 166 | 81.9 (75.3, 87.1) | 0.359 (0.237, 0.545) | 0.077 (0.025, 0.240) |
|         | Both | 300 | 84.2 (79.6, 88.0) | 0.414 (0.300, 0.571) | 0.094 (0.042, 0.211) |
|         | Dry season | Dam | 147 | 54.4 (46.3, 62.4) | 0.085 (0.052, 0.138) | 0.002 (0.000, 3.270) |
|         | No Dam | 162 | 49.1 (41.4, 56.8) | 0.072 (0.044, 0.118) | 0.001 (0.000, 2.630) |
|         | Both | 309 | 51.6 (46.0, 57.2) | 0.078 (0.055, 0.110) | 0.001 (0.000, 6.680) |

*For each antigen, a seropositivity cut-off was estimated using combined log\(_{10}\)-transformed antibody OD data from both communities over the two survey time points (calculated as the back-transformed log\(_{10}\)-mean OD of the negative distribution + log\(_{10}\)-three times the standard deviation, Fig 2). doi:10.1371/journal.pone.0167175.t003**
against CelTOS during the rainy season, but anti-CSP antibody formation rate also reduces significantly compared to anti-AMA1 antibodies during the dry season.

Estimates of $\rho$ for all three antigen-specific antibodies measured were statistically similar to the corresponding $\lambda$ estimates for the same antigens, with the exception of the combined rainy season data for anti-CSP antibodies ($\lambda = 0.414, \, 95\% CI 0.300–0.571; \, \rho = 0.094 (0.042–0.211, Table 3$). While this difference in anti-CSP $\lambda$ and $\rho$ estimates point to a potential difference in the rates of formation and decay of anti-CSP antibodies, this data comparison generally suggests that antibody levels are maintained over time since they are formed and degraded at similar rates. There were also no significant differences amongst the antigen-specific antibody $\rho$ across communities and survey seasons (Table 3).

Currently available models are designed to estimate the annual rates of seroconversion and seroreversion, and the single $\lambda$ and $\rho$ values that are estimated as outputs may not reflect the earlier observed changes in antibody levels and seroprevalence between the two survey time points within the same year. Thus with the current design of these models, seroconversion and

---

**Fig 3. Seroprevalence curves for rainy season survey.** Seroprevalence curves represent the rate at which individuals become seropositive to specific antigens. In each graph, points represent age seroprevalence (divided into deciles), unbroken lines represent maximum likelihood curves and broken lines represent 95% confidence intervals.

doi:10.1371/journal.pone.0167175.g003
seroreversion rate estimates may not detect the observed changes in antigen-specific antibody levels and seroprevalence between the two sampling periods.

### Discussion

Malaria elimination is high on the agenda of control programmes in many malaria-endemic countries and a continued sustenance of control efforts as well as effective monitoring of disease transmission is necessary in these areas to ensure success. There are a number of proven malaria controls tools which continue to be deployed in areas where transmission is believed to still be on-going, but these currently available tools for monitoring transmission and the success of such control efforts have serious limitations, especially when transmission levels fall below the detection limits of these tools [3,20,28]. There is therefore the need to develop more sensitive tools for monitoring low levels of transmission to ensure successful disease elimination and prevent the resurgence of severe disease in previously semi-immune individuals due
to declining immunity as a direct result of declining transmission [29–31]. Transmission monitoring is also important as it can inform about the appropriate timing of control interventions such as drug and vaccine trials. Mathematical models that estimate the rate of antibody seroconversion against mostly blood stage parasite antigens are gaining relevance [2,14,27,32], but a difficulty with this approach has been the identification of appropriate antigen targets since the levels of specific antibodies to these targets must reflect any changes in transmission patterns [20].

Using the reversible catalytic model, we have previously demonstrated the usefulness of the seroprevalence of anti-CSP antibody as a marker for malaria transmission intensity in an area of very low transmission in Ghana [10]. Using this model, the short-lived nature of anti-CSP antibodies was demonstrated by the observation that these antibodies developed at a slower rate compared to antibodies to the blood stage antigen AMA1 but waned at a significantly faster rate than anti-AMA1 antibodies [10]. In the current study, we sought to further assess these models for estimation of short term changes in transmission by measuring and comparing specific antibody levels against CSP, CelTOS and AMA1 in the plasma of individuals living in an area of seasonal malaria transmission and estimating the seroconversion and seroreversion rates of these specific antibodies.

Parasite prevalence was generally not different between the two communities but was significantly higher in all age groups during the rainy season when compared to the dry season in both communities (Table 1). The only exception to this was the similar parasite prevalence levels in the 6–15 year old group between the rainy and dry seasons at the dam site (Table 1). While this generally reflects the higher preponderance of vectors and hence the extent of disease transmission during the rainy season, the observed high parasite prevalence in the 6–15 year old group suggests a greater exposure of this age group to parasites. Similar findings of high parasite prevalence in this age group have been observed and reported elsewhere [33–36].

Antibody levels against the two sporozoite-specific antigens (CSP, CelTOS) were higher during the rainy season when compared to their levels during the dry season for all age groups in the two communities. These changes reflected the pattern of transmission and support the proposed use of anti-sporozoite antibodies as transmission monitoring markers [10]. With the exception of higher rainy season anti-AMA1 tires in the 1–5 year old group at the dam site, anti-AMA1 antibody titres were similar between seasons for all other age groups within the two communities. Thus anti-AMA1 antibody levels did not reflect the change in transmission over the two clearly marked seasons, making these antibodies less suitable for monitoring short term changes in transmission intensity. Antibody levels against all three antigens were generally comparable between the two communities for all age groups.

Despite the lack of differences in antibody seroprevalence between the two communities for any of the age groups compared, the antibody seroprevalence data presented confirms the potential utility of anti-sporozoite antibodies as surrogate markers for assessing short term changes in malaria transmission intensity. Anti-sporozoite antibody levels were high during the rainy season and decreased significantly to low levels in the dry season (Table 3). Anti-AMA1 antibody seroprevalence was not different between seasons, confirming the persistence of these antibodies and the reduced likelihood of anti-AMA1 antibodies fluctuating with short term changes in transmission intensity [20,37].

The superinfection model, which corrects for the effect of repeated exposures on the rate of antibody decay [21], was used to fit seroprevalence data for the estimation of seroconversion and seroreversion rates. While no changes in λ were observed for cross-sectional data from any of the communities or sampling time points (Figs 3 and 4), it was generally observed that anti-AMA1 and anti-CSP antibodies seroconverted at statistically similar rates during the rainy season but anti-CSP antibody seroconversion was significantly reduced during the dry
season (Table 3). This directly supports the finding that the levels of anti-CSP antibodies, but not anti-AMA1 antibodies, are a good predictor of parasite exposure over time [11–13]. Indeed, anti-AMA1 antibodies seroconverted at similar rates during the rainy and dry seasons, while anti-CSP antibodies seroconverted at a significantly higher rate during the rainy season compared to the dry season (Table 3). These therefore collectively confirm the observations made by comparison of parasite prevalence and antibody levels between the two sampling time points. For all measured antibodies, the generally similar estimates for the rates of seroconversion and seroreversion (Table 3) suggest that antibody levels will most likely remain fairly consistent throughout the year.

The finding that no single cross sectional antibody seroprevalence data, including those of anti-CSP antibodies, was able to predict changes in malaria transmission intensity suggest that the estimation models based on dichotomized antibody data may not be optimal for assessing within year changes in malaria transmission. These antibody seroprevalence models are designed to predict annual changes in seroconversion rates by averaging the patterns of seropositivity changes over an entire year [20,21,32]. This may therefore preclude the possibility of detecting changes in transmission that occur within a 12-month period for areas with seasonal disease transmission. It would thus be important to develop models that can predict seasonal changes in malaria transmission, which would usually occur within four to six months. These dichotomized data-based models may therefore need modification to allow for short term, possibly monthly, estimation of seroconversion and seroreversion rates based on cross-sectional data. Fitting of antibody data to other models may also help improve on the predictive power of data from cross-sectional surveys. For example, recent sero-epidemiology studies have reported more precise parasite exposure rates based on new models that utilize continuous antibody data compared to seroconversion estimates by the catalytic model based on dichotomized antibody data [32,38].

There is also the need to look for additional sporozoite antigens with similar or better transmission monitoring properties, especially since the CSP-based malaria vaccine RTS,S stands the chance of being approved for human use. For communities that may potentially this vaccine, the levels of blood anti-CSP antibodies may be contributed by the vaccine as well as by natural infection and may therefore not necessarily reflect the extent of malaria transmission. A recent study screened over 850 Plasmodium antigens using microarrays and identified a limited number of proteins, including parasite-specific enzymes, that were strongly associated with either short term exposure to parasites or the incidence of clinical disease in individuals in an endemic setting [5].

In summary, the levels and seroprevalence of antibodies against sporozoite antigens may be relevant surrogate markers for monitoring changes in malaria transmission patterns in areas of seasonal disease transmission. The levels and seroprevalence of sporozoite-specific antibodies, especially those against the CSP antigen directly reflected changes in malaria transmission between the rainy and dry seasons. Seroconversion rate estimates for all three assessed markers however did not reflect the marked changes in transmission intensity within a year, and this is most likely due to the fact that the prediction model used is designed to estimate changes occurring over an entire year. It is possible that analysis of data with other models that account for some of the basic assumptions upon which the reversible catalytic and superinfection models are based may yield more detailed and robust data to support this approach to malaria transmission estimation.

Acknowledgments

We would like to thank Mrs. Nana Oye Akuffo, Mr. James Boateng, Ms. Pamela Nai and Mrs. Yvonne Oduah, all of Noguchi Memorial Institute for Medical Research for providing
administrative and technical assistance for this study. Special thanks to Mr. Richard Adade of the GIS & Remote Sensing Unit, Department of Fisheries and Aquatic Sciences, Center for Coastal Management, University of Cape Coast, for rendering the map of the study area (Fig 1).

**Author Contributions**

**Conceptualization:** K. Kusi DD MS K. Koram.

**Data curation:** K. Kusi SB MS.

**Formal analysis:** K. Kusi SB.

**Funding acquisition:** K. Kusi K. Koram.

**Investigation:** K. Kusi EKB BT EKD.

**Methodology:** K. Kusi SB EKB BT EKD DD MS K. Koram.

**Project administration:** K. Kusi.

**Resources:** K. Kusi SB EA SD DD MS K. Koram.

**Supervision:** MS K. Koram.

**Validation:** K. Kusi EKB BT EKD.

**Visualization:** K. Kusi SB.

**Writing – original draft:** K. Kusi SB DD MS K. Koram.

**Writing – review & editing:** K. Kusi SB EA SD MS DD K. Koram.

**References**

1. WHO: World Malaria Report. WHO Document Production Services, Geneva, Switzerland; 2015.
2. Bousema T, Youssef RM, Cook J, Cox J, Alegana VA, Amran J et al.: Serologic markers for detecting malaria in areas of low endemicity, Somalia, 2008. Emerg Infect Dis 2010, 16: 392–399. doi: 10.3201/ eid1603.090732 PMID: 20202412
3. Drakeley CJ, Corran PH, Coleman PG, Tongren JE, McDonald SL, Carneiro I et al.: Estimating medium- and long-term trends in malaria transmission by using serological markers of malaria exposure. Proc Natl Acad Sci U S A 2005, 102: 5108–5113. doi: 10.1073/pnas.0408725102 PMID: 15792998
4. Stewart L, Gosling R, Griffin J, Gesase S, Campo J, Hashim R et al.: Rapid assessment of malaria transmission using age-specific sero-conversion rates. PLoS ONE 2009, 4: e6083. doi: 10.1371/journal.pone.0006083 PMID: 19562032
5. Helb DA, Tetteh KK, Felgner PL, Skinner J, Hubbard A, Arinaitwe E et al.: Novel serologic biomarkers provide accurate estimates of recent Plasmodium falciparum exposure for individuals and communities. Proc Natl Acad Sci U S A 2015, 112: E4438–E4447. doi: 10.1073/pnas.1501705112 PMID: 26216993
6. Braga EM, Carvalho LH, Fontes CJ, Krettli AU: Low cellular response in vitro among subjects with long-term exposure to malaria transmission in Brazilian endemic areas. Am J Trop Med Hyg 2002, 66: 299–303. PMID: 12139224
7. Morais CG, Soares IS, Carvalho LH, Fontes CJ, Krettli AU, Braga EM: Antibodies to Plasmodium vivax apical membrane antigen 1: persistence and correlation with malaria transmission intensity. Am J Trop Med Hyg 2006, 75: 582–587. PMID: 17098677
8. Druilhe P, Pradier O, Marc JP, Mitigben F, Mazier D, Parent G: Levels of antibodies to Plasmodium falciparum sporozoite surface antigen reflect malaria transmission rate and are persistent in the absence of reinfection. Infect Immun 1986, 53: 393–397. PMID: 3525412
9. Nahrendorf W, Scholzen A, Bijker EM, Teirlinck AC, Bastiaens GJ, Schats R et al.: Memory B-cell and antibody responses induced by Plasmodium falciparum sporozoite immunization. J Infect Dis 2014, 210: 1891–1900. doi: 10.1093/infdis/jiu354 PMID: 24970846
10. Kusi KA, Bosomprah S, Doodoo D, Kyei-Baafour E, Dickson EK, Mensah D et al.: Anti-sporozoite antibodies as alternative markers for malaria transmission intensity estimation. Malar J 2014, 13: 103. doi: 10.1186/1475-2875-13-103 PMID: 24635830

11. Campo JJ, Whitman TJ, Frelich D, Burgess TH, Martin GJ, Doolan DL: Toward a surrogate marker of malaria exposure: modeling longitudinal antibody measurements under outbreak conditions. PLoS ONE 2011, 6: e21826. doi: 10.1371/journal.pone.0021826 PMID: 21818270

12. Ramasamy R, Nagendran K, Ramasamy MS: Antibodies to epitopes on merozoite and sporozoite surface antigens as serologic markers of malaria transmission: studies at a site in the dry zone of Sri Lanka. Am J Trop Med Hyg 1994, 50: 537–547. PMID: 7515593

13. Webster HK, Gingrich JB, Wongsrichanalai C, Tulyayon S, Suvarnamanii A, Sookto P et al.: Circumsporozoite antibody as a serologic marker of Plasmodium falciparum transmission. Am J Trop Med Hyg 1992, 47: 489–497. PMID: 14433438

14. Arnold BF, Priest JW, Hamlin KL, Moss DM, Colford JM Jr., Lammie PJ: Serological measures of malaria transmission in Haiti: comparison of longitudinal and cross-sectional methods. PLoS ONE 2014, 9: e93684. doi: 10.1371/journal.pone.0093684 PMID: 24691467

15. Appawu M, Owusu-Agyei S, Dadzie S, Asoala V, Anto F, Koram K et al.: Malaria transmission dynamics at a site in northern Ghana proposed for testing malaria vaccines. Trop Med Int Health 2004, 9: 164–170. PMID: 14728621

16. Koram KA, Owusu-Agyei S, Fryauff DJ, Anto F, Atuguba F, Hodgson A et al.: Seasonal profiles of malaria infection, anaemia, and bednet use among age groups and communities in northern Ghana. Trop Med Int Health 2003, 8: 793–802. PMID: 12950665

17. Browne EN, Maude GH, Binka FN: The impact of insecticide-treated bednets on malaria and anaemia in pregnancy in Kassaena-Nankana district, Ghana: a randomized controlled trial. Trop Med Int Health 2001, 6: 667–676. PMID: 11554333

18. Binka FN, Kubaje A, Adjuik M, Williams LA, Lengeler C, Maude GH et al.: Impact of permethrin impregnated bednets on child mortality in Kassaena-Nankana district, Ghana: a randomized controlled trial. Trop Med Int Health 1996, 1: 147–154. PMID: 8665378

19. Owusu-Agyei S, Awini E, Anto F, Mensah-Afful T, Adjuik M, Hodgson A et al.: Assessing malaria control in the Kassaena-Nankana district of northern Ghana through repeated surveys using the RBM tools. Malar J 2007, 6: 103. doi: 10.1186/1475-2875-6-103 PMID: 17683584

20. Corran P, Coleman P, Riley E, Drakeley C: Serology: a robust indicator of malaria transmission intensity? Trends Parasitol 2007, 23: 575–582. doi: 10.1016/j.pt.2007.08.023 PMID: 17988945

21. Bosomprah S: A mathematical model of seropositivity to malaria antigen, allowing seropositivity to be prolonged by exposure. Malar J 2014, 13: 12. doi: 10.1186/1475-2875-13-12 PMID: 24401111

22. Ampadu B, Akurugu BA, Zango MS, Abanyie SK, Ampofo S: Assessing the Impact of a Dam on the Livelihood of Surrounding Communities: A Case Study of Vea Dam in the Upper East Region of Ghana. Journal of Environment and Earth Science 2015, 5: 20–25.

23. Porter MD, Nicki J, Pool CD, DeBot M, Illam RM, Brando C et al.: Transgenic parasites stably expressing full-length Plasmodium falciparum circumsporozoite protein as a model for vaccine down-selection in mice using sterile protection as an endpoint. Clin Vaccine Immunol 2013, 20: 803–810. doi: 10.1128/CVI.00066-13 PMID: 23536694

24. Bergmann-Leitner ES, Meese RM, de I, V, Savranskaya T, Polhemus M, Ockenhouse C et al.: Immunization with pre-erythrocytic antigen CeITOS from Plasmodium falciparum elicits cross-species protection against heterologous challenge with Plasmodium berghei. PLoS ONE 2010, 5: e12294. doi: 10.1371/journal.pone.0012294 PMID: 20808868

25. Dutta S, Ware LA, Barbosa A, Ockenhouse CF, Lanar DE: Purification, characterization, and immunogenicity of a disulfide cross-linked Plasmodium vivax vaccine candidate antigen, merozoite surface protein 1, expressed in Escherichia coli. Infect Immun 2001, 69: 5464–5470. doi: 10.1128/IAI.69.9.5464-5470.2001 PMID: 11500418

26. Dutta S, Sullivan JS, Grady KK, Haynes JD, Komisar J, Batchelor AH et al.: High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model. PLoS ONE 2009, 4: e8138. doi: 10.1371/journal.pone.0008136 PMID: 19997632

27. Cook J, Reid H, Iavro J, Kuwahata M, Taleo G, Clements A et al.: Using serological measures to monitor changes in malaria transmission in Vanuatu. Malar J 2010, 9: 169. doi: 10.1186/1475-2875-9-169 PMID: 20553604

28. Mbogo CM, Mwangangi JM, Nzovu J, Gu W, Yan G, Gunter JT et al.: Spatial and temporal heterogeneity of Anopheles mosquitoes and Plasmodium falciparum transmission along the Kenyan coast. Am J Trop Med Hyg 2003, 68: 734–742. PMID: 12887036
29. Roca-Feltre A, Carneiro I, Smith L, Schellenberg JR, Greenwood B, Schellenberg D: The age patterns of severe malaria syndromes in sub-Saharan Africa across a range of transmission intensities and seasonality settings. Malar J 2010, 9: 282. doi: 10.1186/1475-2875-9-282 PMID: 20939931

30. Okiro EA, Al Ta'ar A, Rayburn H, Idrò R, Berkley JA, Snow RW: Age patterns of severe paediatric malaria and their relationship to Plasmodium falciparum transmission intensity. Malar J 2009, 8: 4. doi: 10.1186/1475-2875-8-4 PMID: 19128453

31. Idrò R, Aloyo J, Mayende L, Bitarakwate E, John CC, Kivumbi GW: Severe malaria in children in areas with low, moderate and high transmission intensity in Uganda. Trop Med Int Health 2006, 11: 115–124. doi: 10.1111/j.1365-3156.2005.01518.x PMID: 16398762

32. Yman V, White MT, Rono J, Arca B, Osier FH, Troye-Blomberg M et al.: Antibody acquisition models: A new tool for serological surveillance of malaria transmission intensity. Sci Rep 2016, 6: 19472. doi: 10.1038/srep19472 PMID: 26846726

33. Nankabirwa JI, Yeka A, Arinaitwe E, Kigozi R, Drakeley C, Kamya MR et al.: Estimating malaria parasite prevalence from community surveys in Uganda: a comparison of microscopy, rapid diagnostic tests and polymerase chain reaction. Malar J 2015, 14: 528. doi: 10.1186/s12936-015-056-x PMID: 26714465

34. Walldorf JA, Cohoe LM, Coalson JE, Bauleni A, Nakanaunena K, Kapito-Tembo A et al.: School-Age Children Are a Reservoir of Malaria Infection in Malawi. PLoS ONE 2015, 10: e0134061. doi: 10.1371/journal.pone.0134061 PMID: 26207758

35. Umaru ML, Uyaibasi GN: Prevalence of Malaria in Patients Attending the General Hospital Makarfi, Makarfi Kaduna ¶C State, North-Western Nigeria. American Journal of Infectious Diseases and Microbiology 2015, 3: 1–5.

36. Nankabirwa J, Brooker SJ, Clarke SE, Fernando D, Gitonga CW, Schellenberg D et al.: Malaria in school-age children in Africa: an increasingly important challenge. Trop Med Int Health 2014, 19: 1294–1309. doi: 10.1111/tmi.12374 PMID: 25145389

37. Proietti C, Pettinato DD, Kanoi BN, Ntege E, Crisanti A, Riley EM et al.: Continuing intense malaria transmission in northern Uganda. Am J Trop Med Hyg 2011, 84: 830–837. doi: 10.4269/ajtmh.2011.10-0498 PMID: 21540398

38. Pothin E, Ferguson NM, Drakeley CJ, Ghani AC: Estimating malaria transmission intensity from Plasmodium falciparum serological data using antibody density models. Malar J 2016, 15: 79. doi: 10.1186/s12936-016-1121-0 PMID: 26861862